Header cover image

Taiwanese (TAIEX) Pharma Industry Analysis

UpdatedMay 09, 2024
DataAggregated Company Financials
Companies49
  • 7D-1.1%
  • 3M2.6%
  • 1Y3.4%
  • YTDn/a

Over the last 7 days, the Pharma industry has dropped 2.2%, driven by a pullback from Lotus Pharmaceutical of 10%. In contrast, Lumosa Therapeutics has gained 9.6%. This takes the industry's 12 month performance to a gain of 3.6%. Earnings are forecast to grow by 38% annually.

Industry Valuation and Performance

Has the Taiwanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 09 May 2024NT$620.0bNT$101.8bNT$9.3b25.8x66.5x6.1x
Sat, 06 Apr 2024NT$700.0bNT$101.5bNT$9.4b26.7x74.8x6.9x
Mon, 04 Mar 2024NT$657.1bNT$102.0bNT$8.3b23.6x79.4x6.4x
Wed, 31 Jan 2024NT$585.8bNT$101.9bNT$7.8b23.9x75.2x5.8x
Fri, 29 Dec 2023NT$577.1bNT$101.9bNT$7.8b23.9x74.1x5.7x
Sun, 26 Nov 2023NT$570.2bNT$101.6bNT$7.7b22.4x74.5x5.6x
Tue, 24 Oct 2023NT$527.5bNT$101.7bNT$9.6b20.4x54.8x5.2x
Thu, 21 Sep 2023NT$549.4bNT$101.7bNT$9.6b22.2x57.1x5.4x
Sat, 19 Aug 2023NT$543.8bNT$101.7bNT$9.6b21.5x56.5x5.3x
Mon, 17 Jul 2023NT$569.2bNT$98.7bNT$10.1b16.9x56.6x5.8x
Wed, 14 Jun 2023NT$579.4bNT$98.6bNT$10.1b17x57.6x5.9x
Fri, 12 May 2023NT$563.2bNT$92.2bNT$8.6b20.1x65.3x6.1x
Sun, 09 Apr 2023NT$587.2bNT$91.2bNT$8.5b21.1x69.1x6.4x
Tue, 07 Mar 2023NT$565.7bNT$85.0bNT$7.7b24.1x73.7x6.7x
Thu, 02 Feb 2023NT$495.4bNT$84.6bNT$7.9b20x62.8x5.9x
Sat, 31 Dec 2022NT$502.1bNT$84.6bNT$7.9b21.8x63.7x5.9x
Mon, 28 Nov 2022NT$476.9bNT$84.6bNT$7.9b16.3x60.5x5.6x
Wed, 26 Oct 2022NT$382.0bNT$78.9bNT$4.3b16.7x88.3x4.8x
Fri, 23 Sep 2022NT$456.2bNT$78.9bNT$4.3b18.3x105.5x5.8x
Sun, 21 Aug 2022NT$425.3bNT$79.0bNT$4.3b18x97.8x5.4x
Tue, 19 Jul 2022NT$375.6bNT$76.8bNT$4.4b21.5x86x4.9x
Thu, 16 Jun 2022NT$385.2bNT$76.8bNT$4.4b21.3x88.2x5x
Sat, 14 May 2022NT$367.0bNT$76.1bNT$6.3b20.2x58.7x4.8x
Mon, 11 Apr 2022NT$408.2bNT$76.4bNT$6.8b20.9x60.4x5.3x
Wed, 09 Mar 2022NT$385.5bNT$76.5bNT$8.5b19.5x45.3x5x
Fri, 04 Feb 2022NT$379.4bNT$76.7bNT$8.5b18.9x44.8x4.9x
Sun, 02 Jan 2022NT$394.6bNT$76.7bNT$8.5b18.6x46.6x5.1x
Tue, 30 Nov 2021NT$381.5bNT$76.7bNT$8.5b17.8x45.1x5x
Thu, 28 Oct 2021NT$373.6bNT$76.0bNT$10.4b17.2x35.8x4.9x
Sat, 25 Sep 2021NT$357.1bNT$76.0bNT$10.7b18.8x33.3x4.7x
Mon, 23 Aug 2021NT$342.3bNT$76.0bNT$10.7b19.7x31.9x4.5x
Sat, 10 Jul 2021NT$369.1bNT$76.0bNT$10.7b19.1x34.4x4.9x
Price to Earnings Ratio

28.3x


Total Market Cap: NT$354.1bTotal Earnings: NT$12.5bTotal Revenue: NT$74.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Pharma Industry Price to Earnings3Y Average 62.3x202220232024
Current Industry PE
  • Investors are optimistic on the Taiwanese Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 65.6x which is higher than its 3-year average PE of 62.3x.
  • The industry is trading close to its 3-year average PS ratio of 5.5x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 9.3% per year over the last three years.
  • Meanwhile revenues for these companies have grown 11% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Taiwanese Pharma compare with similar industries?

TW Market1.40%
Healthcare0.20%
Pharma-1.14%
Pharma-1.14%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6535 Lumosa TherapeuticsNT$188.509.3%
+NT$2.6b		333.3%PS546.4x
6620 Handa PharmaceuticalsNT$134.509.3%
+NT$1.6b		-17.7%PE26.1x
4123 Center LaboratoriesNT$44.652.3%
+NT$686.1m		0.06%PS22x
1720 Standard Chemical & PharmaceuticalNT$65.904.3%
+NT$482.5m		-3.2%PE14.1x
3705 YungShin Global HoldingNT$50.802.6%
+NT$346.3m		13.5%PE16.4x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

6535

NT$188.50

Lumosa Therapeutics

7D

9.3%

1Y

333.3%

6472

NT$717.00

Bora Pharmaceuticals

7D

-4.7%

1Y

20.9%

4123

NT$44.65

Center Laboratories

7D

2.3%

1Y

0.06%

1760

NT$95.00

Panion & Bf Biotech

7D

-2.5%

1Y

-35.6%

4746

NT$94.00

Formosa Laboratories

7D

-7.4%

1Y

8.2%

3705

NT$50.80

YungShin Global Holding

7D

2.6%

1Y

13.5%

4105

NT$78.60

TTY Biopharm

7D

1.3%

1Y

4.8%

1720

NT$65.90

Standard Chemical & Pharmaceutical

7D

4.3%

1Y

-3.2%

6576

NT$94.40

Foresee Pharmaceuticals

7D

-1.7%

1Y

11.5%

1789

NT$27.65

ScinoPharm Taiwan

7D

-3.5%

1Y

4.7%

6919

NT$377.50

Caliway Biopharmaceuticals

7D

-2.2%

1Y

163.1%

1795

NT$282.00

Lotus Pharmaceutical

7D

-11.0%

1Y

-0.5%

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24
Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

6620

NT$134.50

Handa Pharmaceuticals

7D

9.3%

1Y

-17.7%

4166

NT$27.45

Orient Pharma

7D

5.8%

1Y

27.1%

1271

NT$116.00

SunWay Biotech

7D

4.0%

1Y

139.2%

4743

NT$157.00

Oneness Biotech

7D

-2.2%

1Y

-24.6%